“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Different clones, protocol conditions, instruments, and scoring/readout methods may pose challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic accuracy of using different PD-L1 assays interchangeably for various purposes is unknown. The primary objective of this meta-analysis was to address PD-L1 assay interchangeability based on assay diagnostic accuracy for established clinical uses/purposes. A systematic search of the MEDLINE database using PubMed platform was conducted using “PD-L1” as a search term for 01/01/2015 to 31/08/2018, with limitations “English” and “human”. 2,515 abstracts were reviewed to select for original contributions only. 57 studies on comparison of two or more PD-L1 assays were fully reviewed. 22 publications were selected for meta-analysis. Additional data were requested from authors of 20/22 studies in order to enable the meta-analysis. Modified GRADE and QUADAS-2 criteria were used for grading published evidence and designing data abstraction templates for extraction by reviewers. PRISMA was used to guide reporting of systematic review and meta-analysis and STARD 2015 for reporting diagnostic accuracy study. CLSI EP12-A2 was used to guide test comparisons. Data were pooled using random-effects model. The main outcome measure was diagnostic accuracy of various PD-L1 assays. The 22 included studies provided 376 2×2 contingency tables for analyses. Results of our study suggest that, when the testing laboratory is not able to use an Food and Drug Administration-approved companion diagnostic(s) for PD-L1 assessment for its specific clinical purpose(s), it is better to develop a properly validated laboratory developed test for the same purpose(s) as the original PD-L1 Food and Drug Administration-approved immunohistochemistry companion diagnostic, than to replace the original PD-L1 Food and Drug Administration-approved immunohistochemistry companion diagnostic with a another PD-L1 Food and Drug Administration-approved companion diagnostic that was developed for a different purpose.

[1]  Richard D Riley,et al.  Meta‐analysis of diagnostic test studies using individual patient data and aggregate data , 2008, Statistics in medicine.

[2]  Keith Miller,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics. , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  C. Copie-Bergman,et al.  Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms , 2017, PloS one.

[4]  Matteo Brunelli,et al.  PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists , 2018, The American journal of surgical pathology.

[5]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[6]  Xiandong Lin,et al.  Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer , 2017, Scientific Reports.

[7]  S. Moriyama,et al.  Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma , 2018, Oncotarget.

[8]  Nicole Schechter,et al.  Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma , 2016, Diagnostic Pathology.

[9]  Mogens Vyberg,et al.  Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC) , 2015, Virchows Archiv.

[10]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[11]  Johannes B Reitsma,et al.  STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration , 2016, BMJ Open.

[12]  T. Mok,et al.  Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma , 2018, Modern Pathology.

[13]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[14]  J. Griggs,et al.  Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample , 2016, Breast Cancer Research and Treatment.

[15]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[16]  Hui Yu,et al.  PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  S. Fox,et al.  Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples , 2018, Oncotarget.

[18]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[19]  Clive R. Taylor,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1 Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[20]  Jennifer Won,et al.  Diagnostic Accuracy in Fit-for-Purpose PD-L1 Testing , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[21]  M. Dolled-Filhart,et al.  Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[22]  A. Borczuk,et al.  Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. , 2016, Archives of pathology & laboratory medicine.

[23]  S. Fox,et al.  Comparison of Four PD‐L1 Immunohistochemical Assays in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[25]  C. Copie-Bergman,et al.  Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms , 2017, PloS one.

[26]  Joon-Oh Park,et al.  Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy , 2017, Oncotarget.

[27]  C. Boeckx,et al.  Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system , 2017, Histopathology.

[28]  G H Guyatt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies , 2009, Allergy.

[29]  J. Warner,et al.  Fetal and early‐life origins of allergy , 2014, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[30]  Clive Taylor,et al.  Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[31]  P. Maxwell,et al.  ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  A. Darzi,et al.  Guidelines for Diagnostic Tests and Diagnostic Accuracy in Surgical Research , 2010, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[33]  K. Bloom,et al.  Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  I. Jacobs,et al.  Biosimilars in oncology: from development to clinical practice. , 2014, Seminars in oncology.

[35]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[36]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[37]  Eric Faulkner,et al.  PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics , 2018, Diagnostic Pathology.

[38]  A. Šimundić.  Measures of Diagnostic Accuracy: Basic Definitions , 2009, EJIFCC.

[39]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[40]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[41]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  Haiying Xu,et al.  PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison , 2017, Clinical Cancer Research.

[43]  O. Tawfik,et al.  PD-L1 in breast cancer: comparative analysis of 3 different antibodies. , 2018, Human pathology.

[44]  Clive R. Taylor,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4 Tissue Tools for Quality Assurance in Immunohistochemistry , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[45]  A. Gown,et al.  Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression , 2017, Modern Pathology.

[46]  Linda A Bradley,et al.  Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. , 2014, Archives of pathology & laboratory medicine.

[47]  S. Moriyama,et al.  A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma , 2018, Oncotarget.

[48]  T. Morimoto,et al.  Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  P. Hegde,et al.  Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[50]  R. Røge,et al.  Accurate PD-L1 Protocols for Non–Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3 , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[51]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[52]  N. Le Stang,et al.  Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  A. Vincent-Salomon,et al.  Re: HER2 testing in the real world. , 2003, Journal of the National Cancer Institute.

[54]  J. Juco,et al.  Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients , 2018, Cancer cytopathology.

[55]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[56]  S. Sudarsanam,et al.  A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies , 2018, Journal of Clinical Pathology.

[57]  Jérémie F. Cohen,et al.  STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. , 2015, Radiology.

[58]  P. Bossuyt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations , 2011, Allergy.

[59]  Alan Sharpe,et al.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[60]  L. Siu,et al.  PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. , 2016, JAMA oncology.

[61]  M. Tiemann,et al.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas , 2016, Modern Pathology.

[62]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[63]  Jacqueline A. Hall,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[64]  Alex J Sutton,et al.  Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. , 2002, International journal of epidemiology.

[65]  M. Dolled-Filhart,et al.  Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. , 2016, Archives of pathology & laboratory medicine.

[66]  J. Sandbank,et al.  A Harmonization Study for the Use of 22C3 PD‐L1 Immunohistochemical Staining on Ventana’s Platform , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[67]  C. D'Arrigo,et al.  Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms , 2018, Modern Pathology.